Peter Rossing

Peter Rossing

Clinical Professor

Member of:


    1. 2022
    2. Published

      Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

      FIDELIO-DKD Investigators, F. I., 2022, In: Kidney International Reports. 7, 1, p. 36-45

      Research output: Contribution to journalJournal articleResearchpeer-review

    3. 2021
    4. E-pub ahead of print

      Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial

      Ersbøll, M., Jürgens, M., Hasbak, P., Kjær, Andreas, Wolsk, E., Zerahn, B., Brandt-Jacobsen, N. H., Gæde, P., Rossing, Peter, Faber, J., Inzucchi, S. E., Gustafsson, Finn, Schou, Morten & Kistorp, Caroline Michaela Nervil, 20 Oct 2021, (E-pub ahead of print) In: International Journal of Cardiovascular Imaging.

      Research output: Contribution to journalJournal articleResearchpeer-review

    5. Published

      Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

      Zobel, E. H., Wretlind, A., Ripa, Rasmus Sejersten, Rotbain Curovic, V., von Scholten, B. J., Suvitaival, T., Hansen, T. W., Kjær, Andreas, Legido-Quigley, C. & Rossing, Peter, Sep 2021, In: BMJ open diabetes research & care. 9, 1

      Research output: Contribution to journalJournal articleResearchpeer-review

    6. Published

      Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines

      Stougaard, E. B., Vistisen, D., Persson, F. & Rossing, Peter, Sep 2021, In: Diabetologia. 64, SUPPL 1, p. 319-319 1 p., 606.

      Research output: Contribution to journalConference abstract in journalResearchpeer-review

    7. Published

      Response to Comment on Vistisen et al. A validated prediction model for endstage kidney disease in type 1 diabetes. Diabetes care 2021;44:901–907

      Vistisen, D., Andersen, G. S., Hulman, A., McGurnaghan, S. J., Colhoun, H. M., Henriksen, J. E., Thomsen, R. W., Persson, F., Rossing, Peter & Jørgensen, M. E., Jun 2021, In: Diabetes Care. 44, 6, p. e140-e141 2 p.

      Research output: Contribution to journalComment/debateResearchpeer-review

    8. Published

      A narrative review of new treatment options for chronic kidney disease in type 2 diabetes

      Persson, F., Borg, Rikke & Rossing, Peter, 1 Apr 2021, In: Annals of Translational Medicine. 9, 8, p. 716-716 7 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    9. Published

      SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

      Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., Perreault, L., Rosas, S. E., Rossing, Peter, Sola, L., Vallon, V., Wanner, C. & Perkovic, V., Jan 2021, In: American Journal of Kidney Diseases. 77, 1, p. 94-109 16 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    10. Published

      A New Panel Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population

      CKD-EPI GFR Collaborators, C. G. C., 2021, In: American Journal of Kidney Diseases. 77, 5, p. 673-683

      Research output: Contribution to journalJournal articleResearchpeer-review

    11. Published

      A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes

      Vistisen, D., Andersen, G. S., Hulman, A., McGurnaghan, S. J., Colhoun, H. M., Henriksen, J. E., Thomsen, R. W., Persson, F., Rossing, Peter & Jørgensen, M. E., 2021, In: Diabetes Care. 44, 3, 7 p., dc202586.

      Research output: Contribution to journalJournal articleResearchpeer-review

    12. Published

      A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

      DAPA-CKD Trial Committees and Investigators, D. T. C. A. I., 2021, In: Kidney International. 100, 1, p. 215-224

      Research output: Contribution to journalJournal articleResearchpeer-review

    Previous 1 2 3 4 5 6 7 8 ...33 Next

    ID: 12937790